Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia

Trial Profile

Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 11 May 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 16 Nov 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-003239-47 ).
    • 16 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top